Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Phase 2 Terminated
1 enrolled
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Phase 1/2 Terminated
4 enrolled 30 charts
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Phase 1/2 Terminated
15 enrolled 9 charts
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
Phase 4 Terminated
100 enrolled
Biochemotherapy With Temozolomide for Metastatic Melanoma
Phase 2 Terminated
5 enrolled 5 charts
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
Phase 2/3 Terminated
126 enrolled 9 charts
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
Phase 1 Terminated
18 enrolled
Chemoradiation in Locally Advanced Pancreatic Cancer
Phase 2 Terminated
23 enrolled 8 charts
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Phase 1 Terminated
19 enrolled
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase 2 Terminated
23 enrolled 14 charts
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
Phase 1/2 Terminated
10 enrolled
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Phase 2 Terminated
40 enrolled
Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Terminated
35 enrolled
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Phase 2 Terminated
12 enrolled
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
Phase 2 Terminated
2 enrolled 3 charts
Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Phase 2 Terminated
40 enrolled